Enlarged Ovary in Postmenopausal Women: Clinical Significance and Role of Tumor Markers
An enlarged ovary in a postmenopausal woman is highly concerning for malignancy and requires immediate further evaluation with transvaginal ultrasound with Doppler, followed by CA-125 measurement—but CA-125 should NOT be used alone to rule out malignancy, as it performs worse than ultrasound imaging in distinguishing benign from malignant lesions.
Clinical Significance
The finding of an enlarged ovary on transabdominal ultrasound in a postmenopausal woman carries significant malignancy risk. Normal postmenopausal ovaries should be small and often non-palpable. Any enlargement warrants concern, though the specific ultrasound characteristics determine the actual risk level.
Immediate Next Steps
You must obtain transvaginal ultrasound with color/power Doppler imaging 1. Transabdominal ultrasound alone is insufficient for risk stratification. The transvaginal approach provides superior characterization of:
- Morphologic features: Simple cyst vs. complex cystic vs. solid components
- Presence of papillary projections or solid nodules
- Septal characteristics (thin <3mm vs. thick)
- Vascularity patterns using Doppler to identify neovascularity in solid components
Risk Stratification Using O-RADS
Apply the O-RADS US classification system to categorize malignancy risk 2:
- O-RADS 1-2: Physiologic or benign findings (0-10% malignancy risk)
- O-RADS 3: Low risk (1-10%)
- O-RADS 4: Intermediate risk (10-50%)
- O-RADS 5: High risk (50-100%)
Critical point: Simple cysts in postmenopausal women are benign in 100% of cases 1. However, any complex features elevate concern significantly.
Role of CA-125: Use With Caution
Key Evidence on CA-125 Limitations
CA-125 alone performs WORSE than ultrasound in distinguishing benign from malignant ovarian lesions 1. The O-RADS committee deliberately excluded routine tumor marker use from their risk stratification system because 2:
- False reassurance risk: A normal CA-125 may provide false reassurance in a postmenopausal woman with an intermediate- or high-risk (O-RADS 4 or 5) lesion
- Limited sensitivity: CA-125 may be low in borderline tumors, low-grade malignancies, and mucinous carcinomas
- Context-dependent utility: CA-125 improves specificity ONLY in lesions already suspected to be malignant on ultrasound 1
When CA-125 IS Useful
Measure CA-125 in postmenopausal women when ultrasound shows suspicious features 3, 4, 5:
- Optimal threshold: CA-125 ≥35 U/mL correctly identifies malignancy in 90% of postmenopausal women with pelvic masses 3
- Enhanced specificity: When combined with Doppler showing resistive index <0.5, raising the CA-125 cutoff to 65 U/mL achieves 100% specificity and positive predictive value 1
- Best combination: CA-125 paired with postmenopausal status yields the highest positive likelihood ratio (29.7) for predicting malignancy 5
Practical Algorithm for CA-125 Use
- If O-RADS 1-2: CA-125 not needed; lesion is benign
- If O-RADS 3: Consider CA-125; if elevated (≥35 U/mL), escalate surveillance or proceed to MRI
- If O-RADS 4-5: Obtain CA-125, but do not let a normal value delay referral to gynecologic oncology 2
Role of CEA: Limited Utility
CEA has minimal role in primary ovarian mass evaluation 6. CEA is more relevant for:
- Mucinous tumors: May be elevated in mucinous ovarian neoplasms
- Metastatic disease: Helps identify gastrointestinal primary tumors metastatic to the ovary
Do not routinely order CEA for isolated ovarian enlargement unless ultrasound features suggest metastatic disease (bilateral masses, omental involvement) or mucinous characteristics. The evidence shows CA-125 combined with ultrasound provides superior diagnostic accuracy 6, 5.
Management Algorithm
For O-RADS 1-3 Lesions:
- Simple cysts <5cm: Observation acceptable; no CA-125 needed 1
- Complex features or elevated CA-125: Obtain MRI with IV contrast for further characterization 1
For O-RADS 4 Lesions:
- Measure CA-125
- Consider MRI if diagnosis remains uncertain
- Refer to gynecologic oncologist if CA-125 elevated or imaging highly suspicious
For O-RADS 5 Lesions:
- Direct referral to gynecologic oncologist 2
- Measure CA-125 for surgical planning and staging, not for diagnosis
- Do not delay referral awaiting tumor marker results
Common Pitfalls to Avoid
Relying on CA-125 alone: Never use CA-125 as a standalone test; it must be interpreted with ultrasound findings 1
Missing transvaginal ultrasound: Transabdominal imaging alone is inadequate for risk assessment 1
Omitting Doppler evaluation: Color/power Doppler is essential to differentiate solid components from debris and identify neovascularity 1
Delaying referral for normal CA-125: A normal CA-125 does NOT exclude malignancy in postmenopausal women with suspicious ultrasound features 2, 1
Ordering CEA routinely: CEA adds minimal value unless specific features suggest mucinous or metastatic disease 6
When to Order MRI
MRI with IV contrast is the next step for indeterminate masses (uncertain organ of origin or unclear benign vs. malignant characterization) 1. MRI achieves:
- 91% overall accuracy for diagnosing malignancy
- Superior to CT and Doppler ultrasound for characterizing indeterminate lesions
- Posttest probability of malignancy: 95% in postmenopausal women with suspicious features 1
Order MRI before surgical referral for O-RADS 3-4 lesions when diagnosis remains uncertain after transvaginal ultrasound with Doppler and CA-125 evaluation 1.